G-Hypophos 667

Indications of G-Hypophos 667 Tablet 

Calcium acetate is used to treat hyperphosphatemia and manage hyperphosphatemia in patients with end-stage renal failure.

 

Pharmacology of G-Hypophos 667 Tablet 

When calcium acetate is consumed with food, it reacts with dietary phosphate to generate calcium phosphate, which is insoluble and eliminated in the stool. Treatment with phosphate binders is generally regarded clinically appropriate if serum phosphorus remains below 6.0 mg/dl. At neutral pH, calcium acetate is extremely soluble, making calcium readily available for phosphate binding in the proximal small intestine. Orally administered Calcium Acetate from pharmaceutical dose forms has been shown to have a systemic absorption rate of up to 40% when fasting and up to 30% when not fasting. This range includes data from both healthy and unhealthy sutures.

 

Dosage & Administration of G-Hypophos 667 Tablet 

Adult: Initially 3-4 g daily. Usual range: 6-12 g daily.

To control hyperphosphataemia in chronic renal failure: Initially 1.334 g (338 mg of calcium). May increase dosage gradually according to serum phosphate conc, provided hypercalcaemia does not occur.

 

Interaction of G-Hypophos 667 Tablet 

Calcium Acetate may decrease the bioavailability of tetracycline.

 

Contraindications

Calcium Acetate is contraindicated in patients with hypercalcemia.

 

Side Effects of G-Hypophos 667 Tablet 

Patients have experienced nausea during Calcium Acetate medication in clinical investigations. During treatment with Calcium Acetate, hypercalcemia might arise. Mild hypercalcemia (Ca > 10.5 mg/dl) can go unnoticed or cause constipation, anorexia, nausea, and vomiting. Confusion, delirium, stupor, and coma are all symptoms of severe hypercalcemia (Ca>12 mg/dl). Calcium Acetate's long-term effect on the advancement of vascular or soft-tissue calcification has yet to be determined. Pruritus has been recorded in isolated cases, which could be allergic reactions.

 

Pregnancy & Lactation

Calcium acetate has not been used in animal reproduction studies. Calcium Acetate has not been studied to see if it can harm a fetus or impact reproduction capacity when given to a pregnant woman. Only provide calcium acetate to a pregnant lady if it is really necessary.

There are no good studies in women to determine the harm to an infant when the drug is taken while breastfeeding. Before taking this drug during breastfeeding, weigh the potential advantages against the potential hazards.

 

Precautions & Warnings

When calcium is provided with meals to patients with end-stage renal failure, they may develop hypercalcemia. Calcium Acetate should not be taken with any other calcium supplements.

 

Therapeutic Class

Drugs for reduction of serum phosphorus in patients with ESRD, Minerals in bone formation, Specific mineral preparations

 

Storage Conditions

Store in a cool & dry place at room temperature. Protect from light, heat & moisture.

 

Pharmaceutical Name of G-Hypophos 667 Tablet 

Gonoshasthaya Pharma Ltd

 

Generic of G-Hypophos 667 Tablet 

Calcium Acetate